AFB-M.Tb detection (M.Tb/NTM Detection) by CBNAAT Pleural Fluid
New
2,700.00₹
In stock
Hyderabad
0 Reviews
Test Overview: CBNAAT for M.Tb/NTM Detection (Pleural Fluid)
This test utilizes Cartridge-Based Nucleic Acid Amplification Test (CBNAAT)—commonly known as the GeneXpert assay—to rapidly detect the presence of Mycobacterium tuberculosis (M.Tb) complex DNA in pleural fluid samples. Additionally, it differentiates M.Tb from Nontuberculous Mycobacteria (NTM) and simultaneously detects mutations associated with resistance to Rifampicin, a primary first-line anti-tubercular drug.
Clinical Significance
Pleural tuberculosis often presents as an exudative pleural effusion where traditional Acid-Fast Bacilli (AFB) smear microscopy has very low sensitivity due to the paucibacillary nature (low bacterial load) of the fluid.
Speed and Sensitivity: CBNAAT bridges this gap by amplifying DNA, offering a much higher sensitivity than routine microscopy and delivering results within a few hours (compared to weeks for mycobacterial culture).
NTM Differentiation: Distinguishing between M.Tb and NTM is critical, as the clinical management and antibiotic regimens for NTM infections differ significantly from standard tuberculosis treatment.
Drug Resistance Screening: Early identification of Rifampicin resistance serves as a crucial surrogate marker for multidrug-resistant TB (MDR-TB), allowing clinicians to tailor effective treatment regimens immediately.
This test utilizes Cartridge-Based Nucleic Acid Amplification Test (CBNAAT)—commonly known as the GeneXpert assay—to rapidly detect the presence of Mycobacterium tuberculosis (M.Tb) complex DNA in pleural fluid samples. Additionally, it differentiates M.Tb from Nontuberculous Mycobacteria (NTM) and simultaneously detects mutations associated with resistance to Rifampicin, a primary first-line anti-tubercular drug.
Clinical Significance
Pleural tuberculosis often presents as an exudative pleural effusion where traditional Acid-Fast Bacilli (AFB) smear microscopy has very low sensitivity due to the paucibacillary nature (low bacterial load) of the fluid.
Speed and Sensitivity: CBNAAT bridges this gap by amplifying DNA, offering a much higher sensitivity than routine microscopy and delivering results within a few hours (compared to weeks for mycobacterial culture).
NTM Differentiation: Distinguishing between M.Tb and NTM is critical, as the clinical management and antibiotic regimens for NTM infections differ significantly from standard tuberculosis treatment.
Drug Resistance Screening: Early identification of Rifampicin resistance serves as a crucial surrogate marker for multidrug-resistant TB (MDR-TB), allowing clinicians to tailor effective treatment regimens immediately.
Test Overview: CBNAAT for M.Tb/NTM Detection (Pleural Fluid)
This test utilizes Cartridge-Based Nucleic Acid Amplification Test (CBNAAT)—commonly known as the GeneXpert assay—to rapidly detect the presence of Mycobacterium tuberculosis (M.Tb) complex DNA in pleural fluid samples. Additionally, it differentiates M.Tb from Nontuberculous Mycobacteria (NTM) and simultaneously detects mutations associated with resistance to Rifampicin, a primary first-line anti-tubercular drug.
Clinical Significance
Pleural tuberculosis often presents as an exudative pleural effusion where traditional Acid-Fast Bacilli (AFB) smear microscopy has very low sensitivity due to the paucibacillary nature (low bacterial load) of the fluid.
Speed and Sensitivity: CBNAAT bridges this gap by amplifying DNA, offering a much higher sensitivity than routine microscopy and delivering results within a few hours (compared to weeks for mycobacterial culture).
NTM Differentiation: Distinguishing between M.Tb and NTM is critical, as the clinical management and antibiotic regimens for NTM infections differ significantly from standard tuberculosis treatment.
Drug Resistance Screening: Early identification of Rifampicin resistance serves as a crucial surrogate marker for multidrug-resistant TB (MDR-TB), allowing clinicians to tailor effective treatment regimens immediately.
0 Comments
0 Shares
272 Views
0 Reviews
